AMENDMENT TO THE BIOPHARMACEUTICAL SERVICES AGREEMENTBiopharmaceutical Services Agreement • May 9th, 2012 • Synageva Biopharma Corp • Biological products, (no disgnostic substances)
THIS AMENDMENT (“Amendment”) effective as of April 27, 2012 (“Effective Date”), is between Synageva BioPharma Corp., a Delaware corporation with a principal office at 128 Spring Street, Suite 520, Lexington MA 02421 (phone: 781-357-9900; fax: 781-357-9901) (“Synageva”) and Cytovance Biologics, Inc. a Delaware corporation having its principal place of business at 800 Research Parkway, Suite 200 Oklahoma City, OK 73104 (“Cytovance”).
Cytovance Biologics, Inc. Biopharmaceutical Services Agreement for Synageva BioPharma Corp.Biopharmaceutical Services Agreement • May 9th, 2012 • Synageva Biopharma Corp • Biological products, (no disgnostic substances) • Massachusetts
This Biopharmaceutical Services Agreement (the “Agreement”) dated Feb. 27, 2012 (the “Effective Date”) between Synageva BioPharma Corp., (“Synageva”) a company having a place of business at 128 Spring Street, Suite 520, Lexington, MA 02421 and Cytovance Biologics, Inc. a Delaware corporation (“Cytovance”) having its principal place of business at 800 Research Parkway, Suite 200 Oklahoma City, OK 73104 (each a “Party”, collectively the “Parties”).
